Metabolon plots fast growth as biomarker biz booms

Metabolon's booming biomarker business has triggered fast expansion at the Durham, NC-based biotech company, and its CEO says that he expects to double the size of its workforce over the next two years. Metabolon has about 100 workers these days, including 37 with PhDs. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.